Pacira BioSciences, Inc. reported $746M of revenue over the trailing twelve months, +5.7% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $746M (to Q2 2026). Net income: $15M, trailing twelve months to Q2 2026. Free cash flow: $180M, trailing twelve months to Q2 2026. Operating margin: 2.7%, trailing twelve months to Q2 2026.

PCRXPacira BioSciences, Inc.

Healthcare

$36.41+54% 1Y

$36.41

$19.1652 weeks$36.41

Latest close: a new 52-week highOct 8, 2026what changed →

PCRX as reported

Pacira BioSciences, Inc. reported $746M of revenue over the trailing twelve months, +5.7% on the year before. 11 reported series are charted on this page, each one as filed.

$746M

Revenue, trailing twelve months · to Q2 2026 · +5.7% against the twelve months before

Net income: $15M
Net income · −111% year on year · trailing twelve months to Q2 2026
Free cash flow: $180M
Free cash flow · +53% year on year · trailing twelve months to Q2 2026
Operating margin: 2.7%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PCRX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$746M	+5.7%	Q2 2026
Net income	$15M	−111%	Q2 2026
EPS	$0.35	−113%	Q2 2026
Gross margin	79%	n/a	Q2 2026
Operating margin	2.7%	n/a	Q2 2026
Net margin	2.0%	n/a	Q2 2026
ROE	1.7%	n/a	Q2 2026
ROA	0.95%	n/a	Q2 2026
ROIC	2.5%	n/a	Q2 2026
Free cash flow	$180M	+53%	Q2 2026
P/E	104	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.